{"filing":{"accession_number":"0001213900-26-080203","cik":"0001875091","ticker":"NRSNW","company_name":"NeuroSense Therapeutics Ltd.","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298841-6k_neuro.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1875091/000121390026080203/ea0298841-6k_neuro.htm"},"events":[{"id":19376,"run_id":17435,"accession_number":"0001213900-26-080203","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces NeuroSense's decision to proceed with filing a New Drug Submission (NDS) to Health Canada for PrimeC in ALS, following a constructive Pre-NDS meeting. The disclosure highlights achievement of the primary TDP-43 biomarker endpoint (p=0.0421) and a meaningful 14.9-month median survival benefit (HR 0.35, p=0.0037) from the Phase 2b PARADIGM study. This is a material regulatory milestone in the clinical development pathway for the company's lead product candidate, representing significant progress toward commercialization. While not a discrete event type like M\u0026A or exec change, it is a material operational/strategic advancement in product development that would affect a reasonable investor's assessment of the company's prospects.","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18450,"accession_number":"0001213900-26-080203","item_number":"EX-99.1","item_title":"ea029884101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NeuroSense's decision to proceed with filing a New Drug Submission (NDS) to Health Canada for PrimeC in ALS, following a constructive Pre-NDS meeting. The disclosure highlights achievement of the primary TDP-43 biomarker endpoint (p=0.0421) and a meaningful 14.9-month median survival benefit (HR 0.35, p=0.0037) from the Phase 2b PARADIGM study. This is a material regulatory milestone in the clinical development pathway for the company's lead product candidate, representing significant progress toward commercialization. While not a discrete event type like M\u0026A or exec change, it is a material operational/strategic advancement in product development that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:38:39.548563+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18450,"accession_number":"0001213900-26-080203","item_number":"EX-99.1","item_title":"ea029884101ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces NeuroSense's decision to proceed with filing a New Drug Submission (NDS) to Health Canada for PrimeC in ALS, following a constructive Pre-NDS meeting. The disclosure highlights achievement of the primary TDP-43 biomarker endpoint (p=0.0421) and a meaningful 14.9-month median survival benefit (HR 0.35, p=0.0037) from the Phase 2b PARADIGM study. This is a material regulatory milestone in the clinical development pathway for the company's lead product candidate, representing significant progress toward commercialization. While not a discrete event type like M\u0026A or exec change, it is a material operational/strategic advancement in product development that would affect a reasonable investor's assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:38:39.548563+00:00","company_name":"NeuroSense Therapeutics Ltd.","ticker":"NRSNW","filing_date":"2026-07-22"}]}